Dabigatran Etexilate and Velpatasvir and Sofosbuvir Tablets

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Dabigatran may increase the blood levels and effects of velpatasvir. Combining these medications may increase the risk of anemia and bleeding complications. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Call your doctor promptly if you experience paleness, fatigue, dizziness, fainting, unusual bleeding or bruising, swelling, vomiting, blood in your urine or stools, headache, or weakness during treatment with these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration with inhibitors of P-glycoprotein (P-gp) such as velpatasvir may increase the bioavailability of dabigatran following oral administration of dabigatran etexilate, which is a substrate of the efflux transporter. Pharmacokinetic data are lacking.

MANAGEMENT: Pharmacologic response to dabigatran should be monitored more closely whenever a P-gp inhibitor is added to or withdrawn from therapy, and the dabigatran dosage adjusted as necessary. Patients should be monitored for the development of anemia and bleeding complications during coadministration.

Dabigatran Etexilate

Generic Name: dabigatran

Brand name: Pradaxa

Synonyms: Dabigatran

What is Dabigatran Etexilate?

Velpatasvir and Sofosbuvir Tablets

Generic Name: sofosbuvir / velpatasvir

Brand name: Epclusa

Synonyms: Sofosbuvir and velpatasvir, Sofosbuvir and Velpatasvir

What is Velpatasvir and Sofosbuvir Tablets?